Results 171 to 180 of about 34,322 (240)
Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). [PDF]
Shahrokh DK +9 more
europepmc +1 more source
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting apocrine gland–bearing areas. We report a 38‐year‐old male with a lesion in the left axilla, initially clinically interpreted as HS and resistant to antibiotics.
R. Gervasi +10 more
wiley +1 more source
Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases. [PDF]
Coslovich S +8 more
europepmc +1 more source
ABSTRACT Aim The purpose of this study was to compare the outcome of nonsurgical root canal treatment (RCT) in patients with autoimmune diseases (AD) with the outcome in patients without AD. The null hypothesis was: there is no difference in the outcomes of RCT regardless of the patient group. Results were also compared among AD subgroups: inflammatory
Seoyeon Lee +4 more
wiley +1 more source
Efficacy and Safety of Adalimumab as Monotherapy Versus Adalimumab With Methotrexate for Psoriasis: A Systematic Review. [PDF]
Alanazi AF +8 more
europepmc +1 more source
Is Routine Monitoring of TNF-α Inhibitor Levels and Antibodies in Pediatric IBD Justified in the Era of Personalized Medicine. [PDF]
Pytrus T +5 more
europepmc +1 more source
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu +3 more
wiley +1 more source
Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration. [PDF]
Reig-López J +5 more
europepmc +1 more source
Objective To investigate SARS‐CoV‐2 viral shedding duration in autoimmune patients using B cell depleting (BCD) therapy or tumor necrosis factor inhibitors (TNFi) and immunocompetent comparators. Methods We conducted a matched cohort analysis among participants in POSITIVES, a prospective study enrolling outpatients with acute COVID‐19 within five days
Liya Sisay Getachew +34 more
wiley +1 more source

